Drugs / biricodar
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00003847 | Dec 1998 → Feb 2001 | small cell lung carcinoma | Vertex Pharmaceuticals Incorporated | Terminated | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | biricodar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003847 ↗ |
| Known as | VX-71O-3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL350775 ↗ |
| Action | Inhibit | “Multidrug resistance-associated protein 1 inhibitor” CHEMBL350775 ↗1“P-glycoprotein 1 inhibitor” CHEMBL350775 ↗ |
| Modality | Small molecule | — CHEMBL350775 ↗ |
| Target | ABCB1 | “P-glycoprotein 1 inhibitor” CHEMBL350775 ↗ |
| Target | ABCC1 | “Multidrug resistance-associated protein 1 inhibitor” CHEMBL350775 ↗ |